IRIS Accounts Production v24.3.2.46 01797802 Board of Directors 1.5.23 30.4.24 30.4.24 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh017978022023-04-30017978022024-04-30017978022023-05-012024-04-30017978022022-04-30017978022022-05-012023-04-30017978022023-04-3001797802ns15:EnglandWales2023-05-012024-04-3001797802ns14:PoundSterling2023-05-012024-04-3001797802ns10:Director12023-05-012024-04-3001797802ns10:PrivateLimitedCompanyLtd2023-05-012024-04-3001797802ns10:SmallEntities2023-05-012024-04-3001797802ns10:AuditExempt-NoAccountantsReport2023-05-012024-04-3001797802ns10:SmallCompaniesRegimeForDirectorsReport2023-05-012024-04-3001797802ns10:SmallCompaniesRegimeForAccounts2023-05-012024-04-3001797802ns10:FullAccounts2023-05-012024-04-300179780212023-05-012024-04-3001797802ns10:OrdinaryShareClass12023-05-012024-04-3001797802ns10:Director22023-05-012024-04-3001797802ns10:Director32023-05-012024-04-3001797802ns10:Director42023-05-012024-04-3001797802ns10:CompanySecretary12023-05-012024-04-3001797802ns10:RegisteredOffice2023-05-012024-04-3001797802ns5:CurrentFinancialInstruments2024-04-3001797802ns5:CurrentFinancialInstruments2023-04-3001797802ns5:Non-currentFinancialInstruments2024-04-3001797802ns5:Non-currentFinancialInstruments2023-04-3001797802ns5:ShareCapital2024-04-3001797802ns5:ShareCapital2023-04-3001797802ns5:RetainedEarningsAccumulatedLosses2024-04-3001797802ns5:RetainedEarningsAccumulatedLosses2023-04-3001797802ns5:IntangibleAssetsOtherThanGoodwill2023-05-012024-04-3001797802ns5:PatentsTrademarksLicencesConcessionsSimilar2023-05-012024-04-3001797802ns5:PlantMachinery2023-05-012024-04-3001797802ns5:MotorVehicles2023-05-012024-04-3001797802ns5:ComputerEquipment2023-05-012024-04-3001797802ns5:PatentsTrademarksLicencesConcessionsSimilar2023-04-3001797802ns5:PatentsTrademarksLicencesConcessionsSimilar2024-04-3001797802ns5:PatentsTrademarksLicencesConcessionsSimilar2023-04-3001797802ns5:PlantMachinery2023-04-3001797802ns5:MotorVehicles2023-04-3001797802ns5:ComputerEquipment2023-04-3001797802ns5:PlantMachinery2024-04-3001797802ns5:MotorVehicles2024-04-3001797802ns5:ComputerEquipment2024-04-3001797802ns5:PlantMachinery2023-04-3001797802ns5:MotorVehicles2023-04-3001797802ns5:ComputerEquipment2023-04-3001797802ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-04-3001797802ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-04-3001797802ns5:CurrentFinancialInstruments2023-05-012024-04-3001797802ns5:Non-currentFinancialInstruments2023-05-012024-04-3001797802ns5:DeferredTaxation2023-04-3001797802ns5:DeferredTaxation2023-05-012024-04-3001797802ns5:DeferredTaxation2024-04-3001797802ns10:OrdinaryShareClass12024-04-30
REGISTERED NUMBER: 01797802 (England and Wales)











Unaudited Financial Statements

for the Year Ended 30 April 2024

for

Parburch Medical Developments Limited

Parburch Medical Developments Limited (Registered number: 01797802)






Contents of the Financial Statements
for the Year Ended 30 April 2024




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


Parburch Medical Developments Limited

Company Information
for the Year Ended 30 April 2024







DIRECTORS: R C Parker
Mrs J M Parker
Mrs K Coutts
Ms A J Rooth-Parker





SECRETARY: R C Parker





REGISTERED OFFICE: Crane Court
302 London Road
Ipswich
Suffolk
IP2 0AJ





REGISTERED NUMBER: 01797802 (England and Wales)





ACCOUNTANTS: Knights Lowe Ltd
Chartered Accountants
Crane Court
302 London Road
Ipswich
Suffolk
IP2 0AJ

Parburch Medical Developments Limited (Registered number: 01797802)

Statement of Financial Position
30 April 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 2,880 3,345
Tangible assets 5 40,657 37,244
43,537 40,589

CURRENT ASSETS
Stocks 55,659 57,500
Debtors 6 32,938 31,092
Cash at bank 3,988 12,773
92,585 101,365
CREDITORS
Amounts falling due within one year 7 48,933 50,159
NET CURRENT ASSETS 43,652 51,206
TOTAL ASSETS LESS CURRENT LIABILITIES 87,189 91,795

CREDITORS
Amounts falling due after more than one
year

8

(11,302

)

(21,506

)

PROVISIONS FOR LIABILITIES 9 (10,164 ) (9,311 )
NET ASSETS 65,723 60,978

CAPITAL AND RESERVES
Called up share capital 10 3,000 3,000
Retained earnings 62,723 57,978
SHAREHOLDERS' FUNDS 65,723 60,978

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Parburch Medical Developments Limited (Registered number: 01797802)

Statement of Financial Position - continued
30 April 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 13 February 2025 and were signed on its behalf by:





R C Parker - Director


Parburch Medical Developments Limited (Registered number: 01797802)

Notes to the Financial Statements
for the Year Ended 30 April 2024

1. STATUTORY INFORMATION

Parburch Medical Developments Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable net of VAT and trade discounts. The policies adopted for the recognition of turnover are as follows:

Sale of goods

Turnover from the sale of goods is recognised when significant risks and rewards of ownership of the goods have transferred to the buyer, the amount of turnover can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transaction can be measured reliably. This is usually on the dispatch of the goods.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of twenty years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 20% on reducing balance
Motor vehicles - 20% on reducing balance
Computer equipment - 33% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Parburch Medical Developments Limited (Registered number: 01797802)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

2. ACCOUNTING POLICIES - continued

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, hire purchase accounts, bank facilities and loans with related parties.

Debt instruments that are payable or receivable within one year, such as trade payables or receivables, are measured at the undiscounted amount of the cash or other consideration expected to be paid or received. Debt instruments that are repayable or receivable after one year are initially measured at the present value of the future cash flows and subsequently at amortised cost using the effective interest method.

Financial assets that are measured at cost and amortised cost are assessed at the end of each financial year for evidence of impairment. If objective evidence of impairment is found an impairment loss is recognised in the Income Statement.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2023 - 5 ) .

Parburch Medical Developments Limited (Registered number: 01797802)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

4. INTANGIBLE FIXED ASSETS
Patents
and
licences
£   
COST
At 1 May 2023
and 30 April 2024 9,301
AMORTISATION
At 1 May 2023 5,956
Amortisation for year 465
At 30 April 2024 6,421
NET BOOK VALUE
At 30 April 2024 2,880
At 30 April 2023 3,345

5. TANGIBLE FIXED ASSETS
Plant and Motor Computer
machinery vehicles equipment Totals
£    £    £    £   
COST
At 1 May 2023 123,149 25,664 5,237 154,050
Additions 14,372 - 400 14,772
Disposals (2,667 ) - - (2,667 )
At 30 April 2024 134,854 25,664 5,637 166,155
DEPRECIATION
At 1 May 2023 112,402 855 3,549 116,806
Charge for year 4,678 4,962 1,169 10,809
Eliminated on disposal (2,117 ) - - (2,117 )
At 30 April 2024 114,963 5,817 4,718 125,498
NET BOOK VALUE
At 30 April 2024 19,891 19,847 919 40,657
At 30 April 2023 10,747 24,809 1,688 37,244

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 27,110 29,024
Other debtors 5,828 2,068
32,938 31,092

Parburch Medical Developments Limited (Registered number: 01797802)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts 10,227 9,975
Trade creditors 2,899 11,557
Taxation and social security 27,753 22,353
Other creditors 8,054 6,274
48,933 50,159

The bank loan relates to a government backed business Bounce Back Loan and it carries interest at a rate of 2.5%.

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2024 2023
£    £   
Bank loans 11,302 21,506

The bank loan relates to a government backed business Bounce Back Loan and it carries interest at a rate of 2.5%.

9. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax
Accelerated capital allowances 10,164 9,311

Deferred
tax
£   
Balance at 1 May 2023 9,311
Provided during year 853
Balance at 30 April 2024 10,164

10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
3,000 Ordinary 1 3,000 3,000